About: Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://dx.doi.org/10.1016/j.pharmthera.2011.07.006
Description	Over the past forty years, anthracyclines and ellipticines have attracted attention as promising cytostatics. In this review, we focus on their mechanisms of cytoxicity, DNA-damaging effects and adverse side-effects. We also summarize ways to enhance the therapeutic effects of these drugs together with a decrease in their adverse effects. Current drug design strategies are focused on drug bioavailability and their tissue targeting, whereas drug delivery to specific intracellular compartments is rarely addressed. Therefore, therapies utilizing the antineoplastic activities of anthracyclines and ellipticines combined with novel strategies such as nanotechnologies for safer drug delivery, as well as strategies based on gene therapy, could significantly contribute to medical practice. Over the past forty years, anthracyclines and ellipticines have attracted attention as promising cytostatics. In this review, we focus on their mechanisms of cytoxicity, DNA-damaging effects and adverse side-effects. We also summarize ways to enhance the therapeutic effects of these drugs together with a decrease in their adverse effects. Current drug design strategies are focused on drug bioavailability and their tissue targeting, whereas drug delivery to specific intracellular compartments is rarely addressed. Therefore, therapies utilizing the antineoplastic activities of anthracyclines and ellipticines combined with novel strategies such as nanotechnologies for safer drug delivery, as well as strategies based on gene therapy, could significantly contribute to medical practice. (en)
Title	Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances (en)
skos:prefLabel	Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances (en)
skos:notation	RIV/00216208:11310/12:10126251!RIV13-GA0-11310___
http://linked.open...avai/predkladatel	Přírodovědecká fakulta
http://linked.open...avai/riv/aktivita	I P
http://linked.open...avai/riv/aktivity	I, P(GAP205/10/0228), P(GAP301/10/0356), P(IAA401990701)
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Stiborová, Marie
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Karlova v Praze / Přírodovědecká fakulta
http://linked.open...dnocenehoVysledku	122869
http://linked.open...ai/riv/idVysledku	RIV/00216208:11310/12:10126251
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	induced cardiomyopathy; doxorubicin interactions; electrochemical biosensor; in-vivo; cytochromes P450; phase-II; peroxidase-mediated oxidation; cell-cycle arrest; metastatic breast-cancer; nanocarriers; adduct formation; ellipticine; anthracyclines (en)
http://linked.open.../riv/klicoveSlovo	ellipticine metastatic breast-cancer anthracyclines cell-cycle arrest adduct formation doxorubicin interactions induced cardiomyopathy nanocarriers peroxidase-mediated oxidation phase-II cytochromes P450 electrochemical biosensor in-vivo
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[A68F24C2EDAC]
http://linked.open...i/riv/nazevZdroje	Pharmacology and Therapeutics
http://linked.open...in/vavai/riv/obor	FR
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...vavai/riv/projekt	Structure and Dynaics of Bioinorganic Complexes Study of contribution of different DNA-damaging mechanisms to toxicity of cytostatics to human chemosensitive and chemoresistant neuroblastomas Study of binding of platinum cytostatics to DNA structure; Influence of metallothionein
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	133
http://linked.open...iv/tvurceVysledku	Adam, Vojtěch Burda, Jaroslav Eckschlager, Tomáš Frei, Eva Hraběta, Jan Kizek, René Stiborová, Marie Smutný, Svatopluk
http://linked.open...ain/vavai/riv/wos	000299979600003
issn	0163-7258
number of pages	14 (xsd:int)
http://bibframe.org/vocab/doi	10.1016/j.pharmthera.2011.07.006
http://localhost/t...ganizacniJednotka	11310
is http://linked.open...avai/riv/vysledek of	Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 41 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software